Trial
NCT03296033
Residual Anti-Xa Activity After Last Treatment Dose of Enoxaparin
Phase IVTERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Wake Forest University Health Sciences
Collaborators
—
Condition
Anticoagulants and Bleeding Disorders
Intervention
Enoxaparin
Why stopped
enrollment proved to be a challenge due to the changing of the guidelines for bridging off the new anticoagulants that are being prescribed
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-10-05